Peripheral Artery Disease

Peripheral artery disease (PAD) involves atherosclerosis mainly in the extremities, especially in the legs and feet that lead to ischemia. Untreated, PAD can progress to critical limb ischemia (CLI), also called chronic limb-threatening ischemia (CLTI), which will lead to foot or leg amputation. The mortality rate for these CLI amputees is 70% within three years. There is currently an epidemic of PAD and CLI in the U.S. The majority of patients are defined by health disparities concentrated in the Black, Latino, Native American populations in both rural and low-income urban areas. A large number of PAD patients have other comorbities, with diabetes being one a primary issue.

New guidelines help interventional cardiologists manage chronic venous disease
"These recommendations will help ensure that patient care remains both consistent and personalized," SCAI President Srihari S. Naidu, MD, explained.
Popular obesity drugs limit amputations, heart issues among patients with peripheral artery disease
Semaglutide, tirzepatide and other GLP-1 drugs appear to provide significant value for patients with moderate PAD.
New-look peripheral stent with expandable spikes receives FDA’s de novo classification
California-based Reflow Medical gained the approval after submitting data from the DEEPER REVEAL clinical trial. The device was associated with a high success rate and improved outcomes in CLTI patients.
Late-breaking cardiovascular drug trials took center stage at ACC.25
Richard Kovacs, MD, detailed some the most important late-breaking cardiology pharmacology trials presented at ACC.25.
‘A practice-changing trial’: Semaglutide linked to key benefits for PAD patients with diabetes
Patients who present with type 2 diabetes and PAD often face substantial mobility issues. According to new data presented at ACC.25, however, treatment with semaglutide could represent a major step forward for this high-risk population.

Society Society for Cardiovascular Angiography and Interventions (SCAI) President James Hermiller, MD, discusses achievements of SCAI in 2024. #SCAI

SCAI president reviews achievements in interventional cardiology in 2024

SCAI President James Hermiller, MD, recently outlined the key achievements for 2024, including creation of the first interventional cardiology match program, successful advocacy and efforts to increase women in the field.

Industry concerns over paclitaxel-coated devices may have put PAD patients at risk

Back in 2019, the FDA issued a warning about the use of paclitaxel-coated devices when treating peripheral artery disease. The agency took back that warning in 2023, but it appears to have made a significant impact on patient care.

Video interview with J.D. Corl, MD, explaining the use of the new E8 and Javelin Shockwave IVL catheters in PAD.

New balloonless IVL catheter offers an alternative to atherectomy in tight lesions, CTOs

J.D. Corl, MD, shared his experience using two new IVL catheters from Shockwave Medical to treat patients with heavily calcified peripheral arteries. He considers both new devices a significant upgrade.

The Abbott Esprit BTK everolimus-eluting biosorbable scaffold system for below the knee peripheral artery disease on display at TCT 2024. Photo by Dave FornellTCTn 2024 DF

Bioresorbable BTK stent superior to ballon angioplasty at 2 years

Late-breaking data from the LIFE-BTK clinical trial showed that the Esprit BTK bioresorbable scaffold system offered better two-year outcomes than balloon angioplasty in severe peripheral artery disease (PAD) below the knee.

Shockwave Javelin Peripheral IVL Catheter

Shockwave Medical’s IVL technology delivers more positive outcomes for PAD patients

Multiple late-breaking presentations at VIVA 2024 in Las Vegas focused on the benefits of treating peripheral artery disease with the company's intravascular lithotripsy portfolio.

Americans know very little about vascular health, prompting surgeons to speak out

Many Americans have never heard of peripheral artery disease or other common vascular conditions. In fact, a vast majority are not sure what vascular surgeons do.

Pedro Martinez Clark, MD, explains treatment options for peripheral artery disease (PAD) patients.

PAD patients have a wide variety of treatment options

Patients often have misconceptions about the different PAD treatments that are currently available. Pedro Martinez Clark, MD, outlined those options for a new video interview.

Shockwave Medical, a Johnson & Johnson MedTech company, has officially launched its Shockwave E8 Peripheral IVL Catheter in the United States. Shockwave’s E8 catheter was designed specifically to treat patients with calcified femoropopliteal and below-the-knee (BTK) peripheral artery disease (PAD), including those diagnosed with complex chronic limb-threatening ischemia (CLTI).

Shockwave Medical launches new FDA-approved IVL catheter for PAD, CLTI

The new device, already cleared by the FDA, was designed to treat femoropopliteal and below-the-knee PAD.

Peripheral Artery Disease

New guidelines help interventional cardiologists manage chronic venous disease

Popular obesity drugs limit amputations, heart issues among patients with peripheral artery disease

New-look peripheral stent with expandable spikes receives FDA’s de novo classification

Late-breaking cardiovascular drug trials took center stage at ACC.25

‘A practice-changing trial’: Semaglutide linked to key benefits for PAD patients with diabetes